Allain Thibeault Ferhat on Muck Rack

Allain Thibeault Ferhat

As seen in: Nature, Wiley Online Library
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Allain Thibeault

Contact Allain Thibeault, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

A holistic prognostic model for leukemia-free survival after allogeneic transplantation in acute leukemia

|
By Alexandros Spyridonidis, Allain Thibeault Ferhat, Jacques Emmanuel Galimard, Thomas Schroeder, Regis de Latour, Nicolaus Kröger, Didier Blaise, Matthias Stelljes, Matthias Eder, Tobias Gedde-Dahl, Igor Wolfgang Blau, Ibrahim Yakoub-Agha, Edouard Forcade, Anne Huynh, Francesca Kinsella, Hélène Labussiere-Wallet, Jakob Passweg, Robert Zeiser, Mohamed Nabil Houhou, Bipin N. Savani, Roni Shouval, Jurjen Versluis, Mohamad Mohty Verified, Fabio Ciceri, Annalisa Ruggeri
| Nature Verified
Abstract Allogeneic hematopoietic cell transplantation (allo-HCT) can cure acute leukemia, but relapse and non-relapse mortality restrict its success. Existing models focus on single prognostic areas and are not designed to predict leukemia-free survival (LFS), the outcome that best reflects allo-HCT’s curative intent.
Open in Who Shared Issue with article?

T-cell replete haploidentical transplantation compared to mismatched unrelated allogeneic transplantation with post-transplantation cyclophosphamide in patients with secondary acute myeloid leukemia in first complete remission: A study from the ALWP/EBMT

|
By Sarah Kayser, Arnon Nagler, Allain Thibeault Ferhat, Jaime Sanz, Raynier Devillier, Yener Koc, Anna Maria Raiola, Alessandro Busca, Alexander Kulagin, Jan Vydra, Maija Itälä-Remes, Stefania Bramanti, Zafer Gülbas, Jiri Pavlu, Montserrat Rovira, Simona Sica, Alessandro Rambaldi, Eolia Brissot, Ali Bazarbachi, Mohamad Mohty Verified, Fabio Ciceri
| Nature Verified
Abstract Allogeneic hematopoietic stem cell transplantation (HSCT) remains the only curative option for secondary acute myeloid leukemia (sAML). Post-transplant cyclophosphamide has improved graft-versus-host disease (GVHD) prophylaxis, enabling the broader use of alternative donors.
Open in Who Shared Issue with article?

Non‐T‐Depleted Haploidentical Transplantation Compared to Allogeneic Transplantation From Matched Siblings or Unrelated Donors in Patients With Secondary AML in First Complete Remission: A Study From the ALWP/EBMT

|
By Arnon Nagler, Sarah Kayser, Allain Thibeault Ferhat, Sorbonne Paris France
| Wiley Online Library Verified
1 Introduction Secondary acute myeloid leukemia (sAML) is a distinct form of acute myeloid leukemia (AML) that arises following an antecedent hematological disorder, such as myelodysplastic syndrome (MDS) or myeloproliferative disorder (MPD), or as a consequence of prior neoplastic therapy [1-6].
Open in Who Shared Issue with article?
See all 3 articles
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified